Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$477.70 USD
+5.79 (1.23%)
Updated Oct 25, 2024 03:59 PM ET
After-Market: $477.88 +0.18 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$477.70 USD
+5.79 (1.23%)
Updated Oct 25, 2024 03:59 PM ET
After-Market: $477.88 +0.18 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights: Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc.
by Zacks Equity Research
Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc. are included in this blog.
Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.
Will Lower Aggregate Revenues Hurt Intel's (INTC) Q4 Earnings?
by Zacks Equity Research
Intel's (INTC) performance in fourth-quarter 2021 is likely to reflect headwinds in the enterprise business of the data center segment.
Silicon Motion (SIMO) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Silicon Motion's (SIMO) performance in the fourth quarter of 2021 is likely to have benefited from increased sales of SSD and eMMC and UFS controllers.
PTC Gearing Up for Q1 Earnings: What is in the Offing?
by Zacks Equity Research
PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $228.08, marking a -0.23% move from the previous day.
Will Higher Revenues Drive Corning's (GLW) Q4 Earnings?
by Zacks Equity Research
Corning's (GLW) performance in the fourth quarter of 2021 is likely to have been primarily driven by growth in the Optical Communications business.
6 Must-Buy Large-Cap Stocks Ahead of Q4 Earnings Next Week
by Nalak Das
Six large-cap companies will report earnings next week. These are: TSLA, URI, FCX, VRTX, STLD and BRO.
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
4 Stocks With Impressive Interest Coverage Ratio to Invest In
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as ArcBest (ARCB), Advanced Micro Devices (AMD), AGCO Corporation (AGCO) and Vertex (VRTX) are sound enough to meet financial obligations.
4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022
by Zacks Equity Research
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
Will Lower Aggregate Revenues Hurt Verizon's (VZ) Q4 Earnings?
by Zacks Equity Research
Verizon's (VZ) performance in the fourth quarter of 2021 is expected to have been affected by the sale of the Verizon Media unit.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $230.84, marking a -0.1% move from the previous day.
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks
by Kinjel Shah
Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.
The Zacks Analyst Blog Highlights: Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc
by Zacks Equity Research
Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc are highlighted in this Analyst Blog article.
Top Analyst Reports for Bank of America, Broadcom & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Broadcom Inc. (AVGO), and Royal Dutch Shell plc (RDS.A).
Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022?
by Zacks Equity Research
Although Moderna's (MRNA COVID-19 vaccine sales are likely to rise, we expect pipeline updates to be the key catalyst for share price movement in 2022.
Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children
by Zacks Equity Research
The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.
Is Vertex (VRTX) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $223.96 in the latest trading session, marking a +0.95% move from the prior day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $221.86 in the latest trading session, marking a -0.3% move from the prior day.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $223.32 in the latest trading session, marking a +0.63% move from the prior day.